Pharmaceutical company Darnitsa announced rebranding and new strategy

Фармкомпания Дарница объявила ребрендинг и новую стратегию

Pharmaceutical company Darnitsa announced a new strategy

The company says that the ultimate goal of the implementation of the updated strategy see the creation of a global pharmaceutical brand.

Pharmaceutical company Darnitsa Wednesday, October 16, in Kiev announced the rebranding and introduced an updated corporate strategy. This was reported by the press service of the company.

“Rebranding is not just a logo change. This new philosophy of doing business, a new development strategy. We set ourselves the goal of creating an international pharmaceutical brand. To this end, we are negotiating a strategic partnership with European and American players of the pharmaceutical market”, – said the Chairman of the Board of Directors Darnitsa Group Dmytro shymkiv.

Фармкомпания Дарница объявила ребрендинг и новую стратегию

photo: press service of the pharmaceutical company Darnitsa

As part of the rebranding introduces a new company logo is the letter D, stylized under a microscope. According to the company, the new logo “symbolizes research, development, innovation, continuous development and search for new solutions.”

Also, the photographs began to change the packaging design of drugs prescription direction.

“The purpose of the redesign is to make the package useful and informative for the patient. The company will apply color coding according to the symptoms of drug and icons to mark the release form. Prescription drugs information about the dosage additionally highlighted”, – said the press service of the company.

Another strategic direction is named “the transformation Darnitsa 100% digital company.”

“We have invested more than 1 500 000 euros in the digitalization of processes and translations of the life cycle of the drug in digital form. The first Ukrainian pharmaceutical manufacturers completely robotsrule composition. Annually invest in development and research of more than 10% of the gross income. In 2018, the amount of such investments amounted to 3 500 000 EUR, but the center has invested in innovative development of more than 200 million euros”, – said schimke.

According to him, thanks to the early plans to become a leader in the production of complex generics.

“According to the who, 15 years in a row leading causes of death are coronary heart disease and stroke. The fight against cardiovascular diseases – the biggest challenge of modern medicine and pharmaceuticals, and Darnitsa ready to become a part of the response to this challenge, ” added the head of the Board of Directors of the company.

The company said that the strategy defines three priorities in the development of the product portfolio: cardiac direction, neurological and solution to the problems of pain.

“In 2018, the center introduced 10 new products in 12 dosage forms, by the end of 2019 will be released 11 brands, and in 2020 planned 14 new products in 29 dosage forms. Now at different stages of development and implementation there are more than 60 medicines”, – said the press service of the company.

We will remind, in the summer of this year, the center announced about joining the European business Association (European Business Assosiation of – EBA).

Sales of drugs in Ukraine are growing by 11% annually – study

News from the Reporter.net Telegram. Subscribe to our channel https://t.me/korrespondentnet

Source